Art

J-GLOBAL ID：201802285837246078   Reference number：18A0664182

Effects of Cardiac Rehabilitation on High-Density Lipoprotein-mediated Cholesterol Efflux Capacity and Paraoxonase-1 Activity in Patients with Acute Coronary Syndrome

急性冠症候群患者における高密度リポ蛋白質に媒介されるコレステロール排出能とパラオキソナーゼ-1活性に対する心臓リハビリテーションの効果

Author (6)： Furuyama Fumiaki (Division of Cardiology, Department of Medicine, Showa University School of Medicine) ,  Koba Shinji (Division of Cardiology, Department of Medicine, Showa University School of Medicine) ,  Yokota Yuya (Division of Cardiology, Department of Medicine, Showa University School of Medicine) ,  Tsunoda Fumiyoshi (Division of Cardiology, Department of Medicine, Showa University School of Medicine) ,  Shoji Makoto (Division of Cardiology, Department of Medicine, Showa University School of Medicine) ,  Kobayashi Youichi (Division of Cardiology, Department of Medicine, Showa University School of Medicine)
Material： Journal of Atherosclerosis and Thrombosis (Web)  (J Atheroscler Thromb (Web))
Volume： 25  Issue： 2  Page： 153-169(J-STAGE)  Publication year： 2018 
JST Material Number： U0153A  ISSN： 1880-3873  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： *Acute coronary syndrome ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0664182&from=J-GLOBAL&jstjournalNo=U0153A") }}

Author keywords (5)： High-density lipoprotein ,  Cholesterol efflux capacity ,  Apolipoprotein A1 ,  Cardiac rehabilitation ,  Paraoxonase-1 activity

JST classification (1)： Treatment for cardiovasular system diseases in general  (GJ05010B)

Substance index (2)： Rosuvastatin ,  Pitavastatin

Reference (53)：

• 1) Brewer Jr HB: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab, 2011; 96: 1246-1257
• 2) Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L: Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation, 2012; 125: 1905-1919
• 3) Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med, 2011; 364: 127-135
• 4) Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, and Shaul PW: HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med, 2014; 371: 2383-2393
• 5) Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D, Mucksavage ML, Luben R, Billheimer J, Kastelein JJ, Boekholdt SM, Khaw KT, Wareham N, Rader DJ: Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol, 2015; 3: 507-513

Terms in the title (7)： 急性冠症候群 ,  患者 ,  高密度リポ蛋白質 ,  コレステロール排出 ,  パラオキソナーゼ ,  活性 ,  心臓リハビリテーション